European Bladder Cancer Therapeutics Market Participants Must Explore New Areas of Drug Development to Offset Impact of Mature Product Lines.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c70537) has announced the addition of Frost & Sullivan's new report: European Bladder Cancer bladder cancer Malignant tumour of the bladder. The most significant risk factor associated with bladder cancer is smoking. Exposure to chemicals called arylamines, which are used in the leather, rubber, printing, and textiles industries, is another risk factor. Therapeutics Markets to their offering. This Frost & Sullivan research titled European Bladder Cancer Therapeutics Markets presents a concise analysis of the market that includes challenges, factors driving growth and the revenue forecasts from 2003 to 2013. The study identifies the competitive opportunities within the market as well as strategies to exploit these opportunities and overcome industry challenges. In this research, Frost & Sullivan's expert analysts thoroughly examine the cytotoxic (chemotherapy therapies) and targeted therapies segments. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research: -Cytotoxic (chemotherapy therapies) -Targeted therapies Technologies The following technologies are covered in this research: -Gene therapy -Cytotoxic drugs -Chemotherapy -Radiotherapy -Immunotherapy treatment -Electromotive (intravesical electric current) Market Overview Incapacity of Existing Bladder Cancer Therapies to Improve Long-term Patient Survival Rates Create Need for Superior Treatment Methods Despite aggressive therapy with curative intent, muscle-invasive diseases continue to be responsible for patient mortality. The failure of several developments to improve the long-term survival rate of patients with bladder cancer is creating the need for new and advanced treatment methods. "As five-year survival five-year survival Epidemiology The timespan that a person survives with a particular dread disease, in particular CA; 5YS facilitates standardization of survival statistics. See Cancer-free survival. rates in patients receiving conventional systemic therapy systemic therapy Therapeutics Any therapy that reaches target tissues via the systemic circulation for metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. disease are poor, there is a huge unmet need for novel treatments that improve survival or increase the therapeutic ratio of systemic therapy," explains the analyst of this research service. Moreover, no new drugs for bladder cancer have entered the market in two decades, which encourages the scope for novel treatments in the market. Emerging treatment options include new cytotoxic drugs, new targeted therapies and new biological treatments, which include gene therapy. If these treatment options can offer greater clinical efficacy compared to existing treatments, it will drive the market immensely. Novel forms of therapy are much needed for patients with metastatic disease in particular, since the current treatment is only chemotherapy and/or radiotherapy. Market Participants Must Explore New Areas of Drug Development and Delivery to Offset Impact of Mature Product Lines Since chemotherapy and immunotherapy treatments have been in the market for decades, they have become heavily dominated by generics and this in turn has limited growth potential. "Companies developing drugs such as cisplatin cisplatin /cis·plat·in/ (sis´plat-in) DDP; a platinum coordination complex capable of producing inter- and intrastrand DNA crosslinks; used as an antineoplastic. cis·plat·in n. , doxorubicin doxorubicin /doxo·ru·bi·cin/ (dok?so-roo´bi-sin) an antineoplastic antibiotic, produced by Streptomyces peucetius, which binds to DNA and inhibits nucleic acid synthesis; used as the hydrochloride salt and as a liposome-encased and methotrexate methotrexate, drug used in halting the growth of actively proliferating tissues. Introduced in the 1950s, it is used in the treatment of leukemia, psoriasis, and non-Hodgkin's lymphoma. need to explore new areas of development and different ways to grow," notes the analyst. "This can extend treatment opportunities, patient groups and could help deliver the drug more effectively." The strategic aim in the mature stage of the product life cycle is to win over customers from competitors and increase usage by offering value-added features such as the drug delivery mechanism. Research is being carried out to improve the outcomes of Mitomycin mitomycin /mi·to·my·cin/ (mi?to-mi´sin) 1. any of a group of antitumor antibiotics (e.g., mitomycin A, B, C) produced by Streptomyces caespitosus. 2. mitomycin C; used as a palliative antineoplastic. and Bacillus Calmette-Guerin (BCG BCG bacille Calmette-Guérin. BCG abbr. 1. bacillus Calmette-Guérin 2. ballistocardiogram BCG, n.pr See bacille Calmette-Guórin. ) through different delivery mechanisms such as electromotive electromotive /elec·tro·mo·tive/ (-mo´tiv) causing electric activity to be propagated along a conductor. (intravesical electric current) drug delivery. For more information visit http://www.researchandmarkets.com/reports/c70537 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion